Caris Life Sciences (CAI) Receivables - Other (2024 - 2026)

Caris Life Sciences' Receivables - Other history runs 3 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• On a quarterly basis, Receivables - Other changed N/A year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $3.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $7.2 million, up 56.52% from the prior year.
• Receivables - Other declined to $3.7 million in Q1 2026 per CAI's latest filing, from $7.2 million in the prior quarter.
• Across five years, Receivables - Other topped out at $11.2 million in Q2 2025 and bottomed at $3.7 million in Q1 2026.
• The 3-year median for Receivables - Other is $7.2 million (2025), against an average of $7.3 million.
• Biggest YoY gain for Receivables - Other was 56.52% in 2025; the steepest drop was 56.52% in 2025.
• Year by year, Receivables - Other stood at $4.6 million in 2024, then soared by 56.52% to $7.2 million in 2025, then plunged by 48.61% to $3.7 million in 2026.
• Per Business Quant, the three latest CAI Receivables - Other figures stand at $3.7 million (Q1 2026), $7.2 million (Q4 2025), and $9.9 million (Q3 2025).